# Perturbation Comparison Report

## Comparison Summary

**Comparison: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')]**

### Pathway Effects

- **Measles**: CHCHD2 activation (NES 0.85), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.68)
- **Wnt signaling pathway**: CHCHD2 activation (NES 1.28), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.66)
- **Gastric cancer**: CHCHD2 activation (NES 1.28), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.90)
- **FoxO signaling pathway**: Both repression, but CHCHD2 is stronger (NES -0.99 vs -0.89)
- **Chemokine signaling pathway**: CHCHD2 activation (NES 1.11), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.67)
- **Breast cancer**: CHCHD2 activation (NES 1.29), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.91)
- **Human T-cell leukemia virus 1 infection**: Both repression, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES -0.49 vs -0.95)
- **Focal adhesion**: CHCHD2 activation (NES 1.04), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.61)
- **MAPK signaling pathway**: CHCHD2 activation (NES 1.10), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.17)
- **cGMP-PKG signaling pathway**: CHCHD2 activation (NES 1.18), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.05)